Investment case
Sanofi
SNY · 2 developments mapped · last assessed 2026-09-06
Market Ontology has mapped 2 macro, policy, and market developments to Sanofi since 2026-09-06. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for SNY yet, so no modelled value is shown. The SNY valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run SNY on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
Direct increase in market opportunity for Dupixent (co-developed with Regeneron), a leading biologic in atopic dermatitis. Increased sales volume and potential for price stability/growth.
· Moves revenue growth rate, market share assumptions, terminal growth rate
What changed, by assumption
- 2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
- 2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-06 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-06 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-06 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-06 | Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand | Bullish | 1-5y | 0.70 |
| 2026-09-06 | Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics | Bullish | 3-12m | 0.80 |